Glenzocimab (ACT017) is a humanized monoclonal antigen‐binding fragment (Fab) directed against the human platelet glycoprotein VI, a key receptor for collagen and fibrin that plays a major role in thrombus growth and stability.
We developed a model to understand the PK/PD properties of this compound and to help with the dose selection. Read more details in our publication in the Journal of Clinical Pharmacology.